BofA lowered the firm’s price target on PTC Therapeutics (PTCT) to $93 from $97 and keeps a Buy rating on the shares. The firm updated estimates after the Q4 report, stating that it continues to be “encouraged” by the early Sephience launch that is tracking in line with the firm’s initial physician survey.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Sephience-Led Growth, Global Expansion, and Robust Pipeline Underpin Buy Rating on PTC Therapeutics
- PTC Therapeutics price target lowered to $86 from $93 at Wells Fargo
- PTC Therapeutics: Sephience Uptake, Advancing Pipeline, and Strengthening Financials Support Buy Rating
- Balanced Outlook on PTC: Sephience-Driven Growth Offset by Duchenne Headwinds and Unmodeled Vatiquinone Upside Supports Hold Rating
- PTC Therapeutics Tops 2025 Revenue Guidance, Boosts Cash